Biomarkers and Predictive Factors for Treatment Response to Tumor Necrosis Factor-α Inhibitors in Patients with Psoriasis

Overview

Journal J Clin Med

Specialty General Medicine

Date 2023 Feb 11

PMID 36769622

Authors

Teppei Hagino

Hidehisa Saeki

Naoko Kanda

Affiliations

Soon will be listed here.

Abstract

We performed a retrospective and observational study of patients with psoriasis. The aim of this study was to define the laboratory indicators reflecting the treatment response to tumor necrosis factor (TNF)-α inhibitors and the predictors for the treatment response. From January 2010 to June 2022, 28, 15 and 12 patients with psoriasis were treated with infliximab (IFX), adalimumab (ADA) and certolizumab pegol (CZP), respectively. The values of C-reactive protein (CRP), platelet to lymphocyte ratio (PLR), neutrophil to lymphocyte ratio and monocyte to lymphocyte ratio decreased in parallel with psoriasis area and severity index (PASI) at weeks 12 and 52 of treatment. The percentage reduction of the CRP was correlated with that of the PASI at week 52 in all patients and subgroups treated with IFX. The percentage reduction of the PLR was correlated with that of the PASI at week 52 in all patients. Linear multivariate regression analyses revealed that the presence of scalp lesions was associated with a high percentage reduction of the PASI at week 52 in the ADA subgroup. The CRP and PLR might act as biomarkers reflecting the treatment response to TNF-α inhibitors in patients with psoriasis. The presence of scalp lesions might be a predictive factor for a high treatment response to ADA in patients with psoriasis.

Citing Articles

The Association of Inflammatory Indexes Derived from Peripheral Blood Cell Count and Clinical Signs with Response to Treatment with Dupilumab in Pediatric Patients with Moderate-to-Severe Atopic Dermatitis.

Zhang L, Pi J, Wang J, Chen J, Zhang Y, Li J J Inflamm Res. 2025; 18():271-282.

PMID: 39802504 PMC: 11724695. DOI: 10.2147/JIR.S501883.

Association of METS-IR index with psoriasis in US adults: a cross-sectional study.

Liu H, Liu C, Wang T, Fang D Sci Rep. 2024; 14(1):26123.

PMID: 39478034 PMC: 11525547. DOI: 10.1038/s41598-024-77784-x.

Blood-Count-Derived Inflammatory Markers as Predictors of Response to Biologics and Small-Molecule Inhibitors in Psoriasis: A Multicenter Study.

Morariu S, Cotoi O, Tiuca O, Baican A, Gheuca-Solovastru L, Decean H J Clin Med. 2024; 13(14).

PMID: 39064032 PMC: 11277525. DOI: 10.3390/jcm13143992.

Increased Neutrophil-Lymphocyte Ratio and Platelet-Lymphocyte Ratio in Chronic and Severe Urticaria.

Weissmann S, Burrack N, Golan-Tripto I, Horev A Acta Derm Venereol. 2024; 104:adv23932.

PMID: 38576090 PMC: 11005174. DOI: 10.2340/actadv.v103.23932.

Real-world effectiveness and safety of bimekizumab in Japanese patients with psoriasis: A single-center retrospective study.

Hagino T, Saeki H, Fujimoto E, Kanda N J Dermatol. 2024; 51(5):649-658.

PMID: 38482898 PMC: 11484122. DOI: 10.1111/1346-8138.17186.

References

. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001; 69(3):89-95. DOI: 10.1067/mcp.2001.113989. View

Asahina A, Umezawa Y, Yanaba K, Nakagawa H . Serum C-reactive protein levels in Japanese patients with psoriasis and psoriatic arthritis: Long-term differential effects of biologics. J Dermatol. 2015; 43(7):779-84. DOI: 10.1111/1346-8138.13213. View

Beygi S, Lajevardi V, Abedini R . C-reactive protein in psoriasis: a review of the literature. J Eur Acad Dermatol Venereol. 2013; 28(6):700-11. DOI: 10.1111/jdv.12257. View

Lambert B, Carron P, DAsseler Y, Bacher K, Van den Bosch F, Elewaut D . Tc-labelled S-HYNIC certolizumab pegol in rheumatoid arthritis and spondyloarthritis patients: a biodistribution and dosimetry study. EJNMMI Res. 2016; 6(1):88. PMC: 5151115. DOI: 10.1186/s13550-016-0245-0. View

Li J, Franco R, Wang Y, Pan H, Eaton D, Cheng T . Megakaryocytic differentiation of HIMeg-1 cells induced by interferon gamma and tumour necrosis factor alpha but not by thrombopoietin. Cytokine. 1999; 10(11):880-9. DOI: 10.1006/cyto.1998.0345. View

Lee H, Kim Y, Kim G, Ahn E, So M, Sohn D . Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratio as predictors of 12-week treatment response and drug persistence of anti-tumor necrosis factor-α agents in patients with rheumatoid arthritis: a retrospective chart review analysis. Rheumatol Int. 2019; 39(5):859-868. DOI: 10.1007/s00296-019-04276-x. View

Sola-Ortigosa J, Sanchez-Regana M, Umbert-Millet P . Efficacy of adalimumab in the treatment of psoriasis: a retrospective study of 15 patients in daily practice. J Dermatolog Treat. 2011; 23(3):203-7. DOI: 10.3109/09546634.2010.519376. View

Annen S, Horiguchi G, Teramukai S, Ichiyama S, Ito M, Hoashi T . Association of Transition of Laboratory Markers with Transition of Disease Activity in Psoriasis Patients Treated with Biologics. J Nippon Med Sch. 2023; 89(6):587-593. DOI: 10.1272/jnms.JNMS.2022_89-613. View

Sen B, Rifaioglu E, Ekiz O, Inan M, Sen T, Sen N . Neutrophil to lymphocyte ratio as a measure of systemic inflammation in psoriasis. Cutan Ocul Toxicol. 2013; 33(3):223-7. DOI: 10.3109/15569527.2013.834498. View

10.

Gooderham M, Lynde C, Turchin I, Avadisian M, Labelle M, Papp K . Real-world, long-term treatment patterns of commonly used biologics in Canadian patients with moderate-to-severe chronic plaque psoriasis. J Dermatol. 2021; 49(1):95-105. PMC: 9298415. DOI: 10.1111/1346-8138.16214. View

11.

Najar Nobari N, Shahidi Dadras M, Nasiri S, Abdollahimajd F, Gheisari M . Neutrophil/platelet to lymphocyte ratio in monitoring of response to TNF-α inhibitors in psoriatic patients. Dermatol Ther. 2020; 33(4):e13457. DOI: 10.1111/dth.13457. View

12.

Barker T, Fulde G, Moulton B, Nadauld L, Rhodes T . An elevated neutrophil-to-lymphocyte ratio associates with weight loss and cachexia in cancer. Sci Rep. 2020; 10(1):7535. PMC: 7200806. DOI: 10.1038/s41598-020-64282-z. View

13.

Kaya T, Acikgoz S, Yildirim M, Nalbant A, Altas A, Cinemre H . Association between neutrophil-to-lymphocyte ratio and nutritional status in geriatric patients. J Clin Lab Anal. 2018; 33(1):e22636. PMC: 6430358. DOI: 10.1002/jcla.22636. View

14.

Lee J, Kim N, Na S, Youn Y, Shin C . Reference values of neutrophil-lymphocyte ratio, lymphocyte-monocyte ratio, platelet-lymphocyte ratio, and mean platelet volume in healthy adults in South Korea. Medicine (Baltimore). 2018; 97(26):e11138. PMC: 6039688. DOI: 10.1097/MD.0000000000011138. View

15.

Zangrilli A, Caldarola G, Bernardini N, Bavetta M, Graceffa D, Bonifati C . Predictive factors of lack of response to adalimumab among bio-naive patients suffering from moderate-to severe psoriasis: analysis of a multicenter data collection in Italy. Expert Opin Biol Ther. 2021; 21(9):1291-1298. DOI: 10.1080/14712598.2021.1948530. View

16.

Norlin J, Nilsson K, Persson U, Schmitt-Egenolf M . Complete skin clearance and Psoriasis Area and Severity Index response rates in clinical practice: predictors, health-related quality of life improvements and implications for treatment goals. Br J Dermatol. 2019; 182(4):965-973. DOI: 10.1111/bjd.18361. View

17.

Khosravi H, Siegel M, Van Voorhees A, Merola J . Treatment of Inverse/Intertriginous Psoriasis: Updated Guidelines from the Medical Board of the National Psoriasis Foundation. J Drugs Dermatol. 2017; 16(8):760-766. View

18.

Asahina A, Kubo N, Umezawa Y, Honda H, Yanaba K, Nakagawa H . Neutrophil-lymphocyte ratio, platelet-lymphocyte ratio and mean platelet volume in Japanese patients with psoriasis and psoriatic arthritis: Response to therapy with biologics. J Dermatol. 2017; 44(10):1112-1121. DOI: 10.1111/1346-8138.13875. View

19.

Aktas Karabay E, Cerman A, Demir D, Kivanc Altunay I . The Effects of Systemic Psoriasis Therapies on the C-Reactive Protein and the Neutrophil-Lymphocyte Ratio. Ann Dermatol. 2021; 31(6):601-610. PMC: 7992605. DOI: 10.5021/ad.2019.31.6.601. View

20.

Bergen L, Petrovic A, Aarebrot A, Appel S . The TNF/IL-23/IL-17 axis-Head-to-head trials comparing different biologics in psoriasis treatment. Scand J Immunol. 2020; 92(4):e12946. DOI: 10.1111/sji.12946. View